Current List of HHS-Certified Laboratories and Instrumented Initial Testing Facilities Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies, 17442-17444 [2015-07423]
Download as PDF
17442
Federal Register / Vol. 80, No. 62 / Wednesday, April 1, 2015 / Notices
competence of individual investigators,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Board of Scientific
Counselors, NIA.
Date: May 19, 2015.
Time: 8:00 a.m. to 8:30 a.m.
Agenda: To review and evaluate personal
qualifications and performance, and
competence of individual investigators.
Place: National Institute on Aging,
Biomedical Research Center, 3rd Floor
Conference Room, 251 Bayview Boulevard,
Baltimore, MD 21224.
Open: 8:30 a.m. to 11:45 a.m.
Agenda: Committee discussion, individual
presentations, laboratory overview.
Place: National Institute on Aging,
Biomedical Research Center, 3rd Floor
Conference Room, 251 Bayview Boulevard,
Baltimore, MD 21224.
Closed: 11:45 a.m. to 12:45 p.m.
Agenda: To review and evaluate personal
qualifications and performance, and
competence of individual investigators.
Place: National Institute on Aging,
Biomedical Research Center, 3rd Floor
Conference Room, 251 Bayview Boulevard,
Baltimore, MD 21224.
Open: 12:45 p.m. to 3:00 p.m.
Agenda: Committee discussion, individual
presentations, laboratory overview.
Place: National Institute on Aging,
Biomedical Research Center, 3rd Floor
Conference Room, 251 Bayview Boulevard,
Baltimore, MD 21224.
Closed: 3:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate personal
qualifications and performance, and
competence of individual investigators.
Place: National Institute on Aging,
Biomedical Research Center, 3rd Floor
Conference Room, 251 Bayview Boulevard,
Baltimore, MD 21224.
Contact Person: Luigi Ferrucci, Ph.D., MD,
Scientific Director, National Institute on
Aging, 251 Bayview Boulevard, Suite 100,
Room 4C225, Baltimore, MD 21224, 410–
558–8110, LF27Z@NIH.GOV.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
Dated: March 26, 2015.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
mstockstill on DSK4VPTVN1PROD with NOTICES
Dated: March 26, 2015.
Carolyn Baum,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–07342 Filed 3–31–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice.
National Institute of Neurological
Disorders and Stroke; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the Board
Jkt 235001
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences, National Institutes of Health,
HHS).
AGENCY:
National Institutes of Health
18:37 Mar 31, 2015
Name of Committee: Board of Scientific
Counselors, National Institute of
Neurological Disorders and Stroke.
Date: May 17–19, 2015.
Time: 7:00 p.m. to 10:30 a.m.
Agenda: To review and evaluate personal
qualifications and performance, and
competence of individual investigators.
Place: Residence Inn Bethesda, 7335
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Alan P. Koretsky, Ph.D.,
Scientific Director, Division of Intramural
Research, National Institute of Neurological
Disorders and Stroke, NIH, 35 Convent Drive,
Room 6A908, Bethesda, MD 20892, (301)
435–2232, koretskya@ninds.nih.gov.
Current List of HHS-Certified
Laboratories and Instrumented Initial
Testing Facilities Which Meet Minimum
Standards To Engage in Urine Drug
Testing for Federal Agencies
[FR Doc. 2015–07337 Filed 3–31–15; 8:45 am]
VerDate Sep<11>2014
of Scientific Counselors, National
Advisory Neurological Disorders and
Stroke.
The meeting will be closed to the
public as indicated below in accordance
with the provisions set forth in sections
552b(c)(6), Title 5 U.S.C., as amended
for the review, discussion, and
evaluation of individual intramural
programs and projects conducted by the
National Institute of Neurological
Disorders and Stroke, including
consideration of personnel
qualifications and performance, and the
competence of individual investigators,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
The Department of Health and
Human Services (HHS) notifies federal
agencies of the laboratories and
Instrumented Initial Testing Facilities
(IITF) currently certified to meet the
standards of the Mandatory Guidelines
for Federal Workplace Drug Testing
SUMMARY:
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
Programs (Mandatory Guidelines). The
Mandatory Guidelines were first
published in the Federal Register on
April 11, 1988 (53 FR 11970), and
subsequently revised in the Federal
Register on June 9, 1994 (59 FR 29908);
September 30, 1997 (62 FR 51118);
April 13, 2004 (69 FR 19644); November
25, 2008 (73 FR 71858); December 10,
2008 (73 FR 75122); and on April 30,
2010 (75 FR 22809).
A notice listing all currently HHScertified laboratories and IITFs is
published in the Federal Register
during the first week of each month. If
any laboratory or IITF certification is
suspended or revoked, the laboratory or
IITF will be omitted from subsequent
lists until such time as it is restored to
full certification under the Mandatory
Guidelines.
If any laboratory or IITF has
withdrawn from the HHS National
Laboratory Certification Program (NLCP)
during the past month, it will be listed
at the end and will be omitted from the
monthly listing thereafter.
This notice is also available on the
Internet at https://beta.samhsa.gov/
workplace.
FOR FURTHER INFORMATION CONTACT:
Giselle Hersh, Division of Workplace
Programs, SAMHSA/CSAP, Room 7–
1051, One Choke Cherry Road,
Rockville, Maryland 20857; 240–276–
2600 (voice), 240–276–2610 (fax).
SUPPLEMENTARY INFORMATION: The
Mandatory Guidelines were initially
developed in accordance with Executive
Order 12564 and section 503 of Pub. L.
100–71. The ‘‘Mandatory Guidelines for
Federal Workplace Drug Testing
Programs,’’ as amended in the revisions
listed above, requires strict standards
that laboratories and IITFs must meet in
order to conduct drug and specimen
validity tests on urine specimens for
federal agencies.
To become certified, an applicant
laboratory or IITF must undergo three
rounds of performance testing plus an
on-site inspection. To maintain that
certification, a laboratory or IITF must
participate in a quarterly performance
testing program plus undergo periodic,
on-site inspections.
Laboratories and IITFs in the
applicant stage of certification are not to
be considered as meeting the minimum
requirements described in the HHS
Mandatory Guidelines. A HHS-certified
laboratory or IITF must have its letter of
certification from HHS/SAMHSA
(formerly: HHS/NIDA), which attests
that it has met minimum standards.
In accordance with the Mandatory
Guidelines dated November 25, 2008
(73 FR 71858), the following HHS-
E:\FR\FM\01APN1.SGM
01APN1
mstockstill on DSK4VPTVN1PROD with NOTICES
Federal Register / Vol. 80, No. 62 / Wednesday, April 1, 2015 / Notices
certified laboratories and IITFs meet the
minimum standards to conduct drug
and specimen validity tests on urine
specimens:
HHS-Certified Instrumented Initial
Testing Facilities:
Gamma-Dynacare Medical
Laboratories
6628 50th Street NW.
Edmonton, AB Canada T6B 2N7
780–784–1190
HHS-Certified Laboratories:
ACM Medical Laboratory, Inc.
160 Elmgrove Park
Rochester, NY 14624
585–429–2264
Aegis Analytical Laboratories, Inc.
345 Hill Ave.
Nashville, TN 37210
615–255–2400
(Formerly: Aegis Sciences
Corporation, Aegis Analytical
Laboratories, Inc., Aegis Analytical
Laboratories)
Alere Toxicology Services
1111 Newton St.
Gretna, LA 70053
504–361–8989/800–433–3823
(Formerly: Kroll Laboratory
Specialists, Inc., Laboratory
Specialists, Inc.)
Alere Toxicology Services
450 Southlake Blvd.
Richmond, VA 23236
804–378–9130
(Formerly: Kroll Laboratory
Specialists, Inc., Scientific Testing
Laboratories, Inc.; Kroll Scientific
Testing Laboratories, Inc.)
Baptist Medical Center-Toxicology
Laboratory
11401 I–30
Little Rock, AR 72209–7056
501–202–2783
(Formerly: Forensic Toxicology
Laboratory Baptist Medical Center)
Clinical Reference Lab
8433 Quivira Road
Lenexa, KS 66215–2802
800–445–6917
DrugScan, Inc.
200 Precision Road, Suite 200
Horsham, PA 19044
800–235–4890
ElSohly Laboratories, Inc.
5 Industrial Park Drive
Oxford, MS 38655
662–236–2609
Fortes Laboratories, Inc.
25749 SW Canyon Creek Road, Suite
600
Wilsonville, OR 97070
503–486–1023
Gamma-Dynacare Medical
Laboratories*
A Division of the Gamma-Dynacare
Laboratory Partnership
VerDate Sep<11>2014
18:37 Mar 31, 2015
Jkt 235001
245 Pall Mall Street
London, ONT, Canada N6A 1P4
519–679–1630
Laboratory Corporation of America
Holdings
7207 N. Gessner Road
Houston, TX 77040
713–856–8288/800–800–2387
Laboratory Corporation of America
Holdings
69 First Ave.
Raritan, NJ 08869
908–526–2400/800–437–4986
(Formerly: Roche Biomedical
Laboratories, Inc.)
Laboratory Corporation of America
Holdings
1904 Alexander Drive
Research Triangle Park, NC 27709
919–572–6900/800–833–3984
(Formerly: LabCorp Occupational
Testing Services, Inc., CompuChem
Laboratories, Inc.; CompuChem
Laboratories, Inc., A Subsidiary of
Roche Biomedical Laboratory;
Roche CompuChem Laboratories,
Inc., A Member of the Roche Group)
Laboratory Corporation of America
Holdings
1120 Main Street
Southaven, MS 38671
866–827–8042/800–233–6339
(Formerly: LabCorp Occupational
Testing Services, Inc.; MedExpress/
National Laboratory Center)
LabOne, Inc. d/b/a Quest Diagnostics
10101 Renner Blvd.
Lenexa, KS 66219
913–888–3927/800–873–8845
(Formerly: Quest Diagnostics
Incorporated; LabOne, Inc.; Center
for Laboratory Services, a Division
of LabOne, Inc.)
MedTox Laboratories, Inc.
402 W. County Road D
St. Paul, MN 55112
651–636–7466/800–832–3244
MetroLab-Legacy Laboratory Services
1225 NE 2nd Ave.
Portland, OR 97232
503–413–5295/800–950–5295
Minneapolis Veterans Affairs Medical
Center
Forensic Toxicology Laboratory
1 Veterans Drive
Minneapolis, MN 55417
612–725–2088
National Toxicology Laboratories, Inc.
1100 California Ave.
Bakersfield, CA 93304
661–322–4250/800–350–3515
One Source Toxicology Laboratory,
Inc.
1213 Genoa-Red Bluff
Pasadena, TX 77504
888–747–3774
(Formerly: University of Texas
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
17443
Medical Branch, Clinical Chemistry
Division; UTMB PathologyToxicology Laboratory)
Pacific Toxicology Laboratories
9348 DeSoto Ave.
Chatsworth, CA 91311
800–328–6942
(Formerly: Centinela Hospital Airport
Toxicology Laboratory)
Pathology Associates Medical
Laboratories
110 West Cliff Dr.
Spokane, WA 99204
509–755–8991/800–541–7891x7
Phamatech, Inc.
15175 Innovation Drive
San Diego, CA 92128
888–635–5840
Quest Diagnostics Incorporated
1777 Montreal Circle
Tucker, GA 30084
800–729–6432
(Formerly: SmithKline Beecham
Clinical Laboratories; SmithKline
Bio-Science Laboratories)
Quest Diagnostics Incorporated
400 Egypt Road
Norristown, PA 19403
610–631–4600/877–642–2216
(Formerly: SmithKline Beecham
Clinical Laboratories; SmithKline
Bio-Science Laboratories)
Quest Diagnostics Incorporated
8401 Fallbrook Ave.
West Hills, CA 91304
818–737–6370
(Formerly: SmithKline Beecham
Clinical Laboratories)
Redwood Toxicology Laboratory
3700650 Westwind Blvd.
Santa Rosa, CA 95403
800–255–2159
Southwest Laboratories
4625 E. Cotton Center Boulevard
Suite 177
Phoenix, AZ 85040
602–438–8507/800–279–0027
STERLING Reference Laboratories
2617 East L Street
Tacoma, Washington 98421
800–442–0438
U.S. Army Forensic Toxicology Drug
Testing Laboratory
2490 Wilson St.
Fort George G. Meade, MD 20755–
5235
301–677–7085
* The Standards Council of Canada
(SCC) voted to end its Laboratory
Accreditation Program for Substance
Abuse (LAPSA) effective May 12, 1998.
Laboratories certified through that
program were accredited to conduct
forensic urine drug testing as required
by U.S. Department of Transportation
(DOT) regulations. As of that date, the
E:\FR\FM\01APN1.SGM
01APN1
17444
Federal Register / Vol. 80, No. 62 / Wednesday, April 1, 2015 / Notices
certification of those accredited
Canadian laboratories will continue
under DOT authority. The responsibility
for conducting quarterly performance
testing plus periodic on-site inspections
of those LAPSA-accredited laboratories
was transferred to the U.S. HHS, with
the HHS’ NLCP contractor continuing to
have an active role in the performance
testing and laboratory inspection
processes. Other Canadian laboratories
wishing to be considered for the NLCP
may apply directly to the NLCP
contractor just as U.S. laboratories do.
Upon finding a Canadian laboratory to
be qualified, HHS will recommend that
DOT certify the laboratory (Federal
Register, July 16, 1996) as meeting the
minimum standards of the Mandatory
Guidelines published in the Federal
Register on April 30, 2010 (75 FR
22809). After receiving DOT
certification, the laboratory will be
included in the monthly list of HHScertified laboratories and participate in
the NLCP certification maintenance
program.
Janine Denis Cook,
Chemist Division of Workplace Programs,
Center for Substance Abuse Prevention,
SAMHSA.
[FR Doc. 2015–07423 Filed 3–31–15; 8:45 am]
BILLING CODE 4162–20–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Toxic Substances and
Disease Registry
[Docket No. ATSDR–2015–0001]
Proposed Substances To Be Evaluated
for Set 29 Toxicological Profiles
Agency for Toxic Substances
and Disease Registry (ATSDR),
Department of Health and Human
Services (HHS).
ACTION: Request for comments on the
proposed substances to be evaluated for
Set 29 toxicological profiles.
AGENCY:
ATSDR is initiating the
development of its 29th set of
toxicological profiles (CERCLA Set 29).
This notice announces the list of
proposed substances that will be
evaluated for CERCLA Set 29
toxicological profile development.
ATSDR’s Division of Toxicology and
Human Health Sciences is soliciting
public nominations from the list of
proposed substances to be evaluated for
toxicological profile development.
ATSDR also will consider the
nomination of any additional, nonCERCLA substances that may have
public health implications, on the basis
mstockstill on DSK4VPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
18:37 Mar 31, 2015
Jkt 235001
of ATSDR’s authority to prepare
toxicological profiles for substances not
found at sites on the National Priorities
List. The agency will do so in order to
‘‘. . . establish and maintain inventory
of literature, research, and studies on
the health effects of toxic substances’’
under CERCLA Section 104(i)(1)(B), to
respond to requests for consultation
under section 104(i)(4), and to support
the site-specific response actions
conducted by ATSDR, as otherwise
necessary.
DATES: Nominations from the Substance
Priority List and/or additional
substances must be submitted within 30
days of the publication of this notice.
ADDRESSES: You may submit
nominations, identified by Docket No.
ATSDR–2015–0001, by any of the
following methods:
*Internet: Access the Federal
eRulemaking portal at https://
www.regulations.gov. Follow the
instructions for submitting comments.
*Mail: Division of Toxicology and
Human Health Sciences, 1600 Clifton
Rd. NE., MS F–57, Atlanta, Ga., 30333.
Instructions: All submissions must
include the agency name and docket
number for this notice. All relevant
comments will be posted without
change. This means that no confidential
business information or other
confidential information should be
submitted in response to this notice.
Refer to the section Submission of
Nominations (below) for the specific
information required.
FOR FURTHER INFORMATION CONTACT: For
further information, please contact
Commander Jessilynn B. Taylor,
Division of Toxicology and Human
Health Sciences, 1600 Clifton Rd. NE.,
MS F–57, Atlanta, Ga., 30333, Email:
tpcandidatecomments@cdc.gov; phone:
1–800–232–4636.
SUPPLEMENTARY INFORMATION: The
Superfund Amendments and
Reauthorization Act of 1986 (SARA) [42
U.S.C. 9601 et seq.] amended the
Comprehensive Environmental
Response, Compensation, and Liability
Act of 1980 (CERCLA or Superfund) [42
U.S.C. 9601 et seq.] by establishing
certain requirements for ATSDR and the
U.S. Environmental Protection Agency
(EPA) with regard to hazardous
substances most commonly found at
facilities on the CERCLA National
Priorities List (NPL). Among these
statutory requirements is a mandate for
the Administrator of ATSDR to prepare
toxicological profiles for each substance
included on the Priority List of
Hazardous Substances. This list
identifies 275 hazardous substances that
ATSDR and EPA have determined pose
PO 00000
Frm 00059
Fmt 4703
Sfmt 4703
the most significant current potential
threat to human health. The availability
of the revised list of the 275 priority
substances was announced in the
Federal Register on May 28, 2014 (79
FR 30613). For prior versions of the list
of substances, see Federal Register
notices dated April 17, 1987 (52 FR
12866); October 20, 1988 (53 FR 41280);
October 26, 1989 (54 FR 43619); October
17,1990 (55 FR 42067); October 17, 1991
(56 FR 52166); October 28, 1992 (57 FR
48801); February 28, 1994 (59 FR 9486);
April 29, 1996 (61 FR 18744); November
17, 1997 (62 FR 61332); October 21,
1999 (64 FR 56792); October 25, 2001
(66 FR 54014); November 7, 2003 (68 FR
63098); December 7, 2005 (70 FR
72840); and March 6, 2008 (73 FR
12178); November 3, 2011 (76 FR
68193).
Substances To Be Evaluated for Set 29
Toxicological Profiles
Each year, ATSDR develops a list of
substances to be considered for
toxicological profile development. The
Set 29 nomination process includes
consideration of all substances on
ATSDR’s Priority List of Hazardous
Substances, also known as the
Substance Priority List (SPL), as well as
other substances nominated by the
public. The 275 substances on the SPL
will be considered for Set 29
Toxicological Profile development. This
list may be found at the following Web
site: www.atsdr.cdc.gov/SPL.
Submission of Nominations for the
Evaluation of Set 29 Proposed
Substances
Today’s notice invites voluntary
public nominations for substances
included on the SPL and for substances
not listed on the SPL. All nominations
should include the full name of the
nominator, affiliation, and email
address. When nominating a non-SPL
substance, please include the rationale
for the nomination. Please note that
email addresses will not be posted on
regulations.gov.
ATSDR will evaluate all data and
information associated with nominated
substances and will determine the final
list of substances to be chosen for
toxicological profile development.
Substances will be chosen according to
ATSDR’s specific guidelines for
selection. These guidelines can be found
in the Selection Criteria announced in
the Federal Register on May 7, 1993 (58
FR 27286–27287). A hard copy of the
Selection Criteria is available upon
request or may be accessed at: https://
www.atsdr.cdc.gov/toxprofiles/
guidance/criteria_for_selecting_tp_
support.pdf.
E:\FR\FM\01APN1.SGM
01APN1
Agencies
[Federal Register Volume 80, Number 62 (Wednesday, April 1, 2015)]
[Notices]
[Pages 17442-17444]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2015-07423]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Current List of HHS-Certified Laboratories and Instrumented
Initial Testing Facilities Which Meet Minimum Standards To Engage in
Urine Drug Testing for Federal Agencies
AGENCY: Substance Abuse and Mental Health Services Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Department of Health and Human Services (HHS) notifies
federal agencies of the laboratories and Instrumented Initial Testing
Facilities (IITF) currently certified to meet the standards of the
Mandatory Guidelines for Federal Workplace Drug Testing Programs
(Mandatory Guidelines). The Mandatory Guidelines were first published
in the Federal Register on April 11, 1988 (53 FR 11970), and
subsequently revised in the Federal Register on June 9, 1994 (59 FR
29908); September 30, 1997 (62 FR 51118); April 13, 2004 (69 FR 19644);
November 25, 2008 (73 FR 71858); December 10, 2008 (73 FR 75122); and
on April 30, 2010 (75 FR 22809).
A notice listing all currently HHS-certified laboratories and IITFs
is published in the Federal Register during the first week of each
month. If any laboratory or IITF certification is suspended or revoked,
the laboratory or IITF will be omitted from subsequent lists until such
time as it is restored to full certification under the Mandatory
Guidelines.
If any laboratory or IITF has withdrawn from the HHS National
Laboratory Certification Program (NLCP) during the past month, it will
be listed at the end and will be omitted from the monthly listing
thereafter.
This notice is also available on the Internet at https://beta.samhsa.gov/workplace.
FOR FURTHER INFORMATION CONTACT: Giselle Hersh, Division of Workplace
Programs, SAMHSA/CSAP, Room 7-1051, One Choke Cherry Road, Rockville,
Maryland 20857; 240-276-2600 (voice), 240-276-2610 (fax).
SUPPLEMENTARY INFORMATION: The Mandatory Guidelines were initially
developed in accordance with Executive Order 12564 and section 503 of
Pub. L. 100-71. The ``Mandatory Guidelines for Federal Workplace Drug
Testing Programs,'' as amended in the revisions listed above, requires
strict standards that laboratories and IITFs must meet in order to
conduct drug and specimen validity tests on urine specimens for federal
agencies.
To become certified, an applicant laboratory or IITF must undergo
three rounds of performance testing plus an on-site inspection. To
maintain that certification, a laboratory or IITF must participate in a
quarterly performance testing program plus undergo periodic, on-site
inspections.
Laboratories and IITFs in the applicant stage of certification are
not to be considered as meeting the minimum requirements described in
the HHS Mandatory Guidelines. A HHS-certified laboratory or IITF must
have its letter of certification from HHS/SAMHSA (formerly: HHS/NIDA),
which attests that it has met minimum standards.
In accordance with the Mandatory Guidelines dated November 25, 2008
(73 FR 71858), the following HHS-
[[Page 17443]]
certified laboratories and IITFs meet the minimum standards to conduct
drug and specimen validity tests on urine specimens:
HHS-Certified Instrumented Initial Testing Facilities:
Gamma-Dynacare Medical Laboratories
6628 50th Street NW.
Edmonton, AB Canada T6B 2N7
780-784-1190
HHS-Certified Laboratories:
ACM Medical Laboratory, Inc.
160 Elmgrove Park
Rochester, NY 14624
585-429-2264
Aegis Analytical Laboratories, Inc.
345 Hill Ave.
Nashville, TN 37210
615-255-2400
(Formerly: Aegis Sciences Corporation, Aegis Analytical
Laboratories, Inc., Aegis Analytical Laboratories)
Alere Toxicology Services
1111 Newton St.
Gretna, LA 70053
504-361-8989/800-433-3823
(Formerly: Kroll Laboratory Specialists, Inc., Laboratory
Specialists, Inc.)
Alere Toxicology Services
450 Southlake Blvd.
Richmond, VA 23236
804-378-9130
(Formerly: Kroll Laboratory Specialists, Inc., Scientific Testing
Laboratories, Inc.; Kroll Scientific Testing Laboratories, Inc.)
Baptist Medical Center-Toxicology Laboratory
11401 I-30
Little Rock, AR 72209-7056
501-202-2783
(Formerly: Forensic Toxicology Laboratory Baptist Medical Center)
Clinical Reference Lab
8433 Quivira Road
Lenexa, KS 66215-2802
800-445-6917
DrugScan, Inc.
200 Precision Road, Suite 200
Horsham, PA 19044
800-235-4890
ElSohly Laboratories, Inc.
5 Industrial Park Drive
Oxford, MS 38655
662-236-2609
Fortes Laboratories, Inc.
25749 SW Canyon Creek Road, Suite 600
Wilsonville, OR 97070
503-486-1023
Gamma-Dynacare Medical Laboratories*
A Division of the Gamma-Dynacare Laboratory Partnership
245 Pall Mall Street
London, ONT, Canada N6A 1P4
519-679-1630
Laboratory Corporation of America Holdings
7207 N. Gessner Road
Houston, TX 77040
713-856-8288/800-800-2387
Laboratory Corporation of America Holdings
69 First Ave.
Raritan, NJ 08869
908-526-2400/800-437-4986
(Formerly: Roche Biomedical Laboratories, Inc.)
Laboratory Corporation of America Holdings
1904 Alexander Drive
Research Triangle Park, NC 27709
919-572-6900/800-833-3984
(Formerly: LabCorp Occupational Testing Services, Inc., CompuChem
Laboratories, Inc.; CompuChem Laboratories, Inc., A Subsidiary of Roche
Biomedical Laboratory; Roche CompuChem Laboratories, Inc., A Member of
the Roche Group)
Laboratory Corporation of America Holdings
1120 Main Street
Southaven, MS 38671
866-827-8042/800-233-6339
(Formerly: LabCorp Occupational Testing Services, Inc.; MedExpress/
National Laboratory Center)
LabOne, Inc. d/b/a Quest Diagnostics
10101 Renner Blvd.
Lenexa, KS 66219
913-888-3927/800-873-8845
(Formerly: Quest Diagnostics Incorporated; LabOne, Inc.; Center for
Laboratory Services, a Division of LabOne, Inc.)
MedTox Laboratories, Inc.
402 W. County Road D
St. Paul, MN 55112
651-636-7466/800-832-3244
MetroLab-Legacy Laboratory Services
1225 NE 2nd Ave.
Portland, OR 97232
503-413-5295/800-950-5295
Minneapolis Veterans Affairs Medical Center
Forensic Toxicology Laboratory
1 Veterans Drive
Minneapolis, MN 55417
612-725-2088
National Toxicology Laboratories, Inc.
1100 California Ave.
Bakersfield, CA 93304
661-322-4250/800-350-3515
One Source Toxicology Laboratory, Inc.
1213 Genoa-Red Bluff
Pasadena, TX 77504
888-747-3774
(Formerly: University of Texas Medical Branch, Clinical Chemistry
Division; UTMB Pathology-Toxicology Laboratory)
Pacific Toxicology Laboratories
9348 DeSoto Ave.
Chatsworth, CA 91311
800-328-6942
(Formerly: Centinela Hospital Airport Toxicology Laboratory)
Pathology Associates Medical Laboratories
110 West Cliff Dr.
Spokane, WA 99204
509-755-8991/800-541-7891x7
Phamatech, Inc.
15175 Innovation Drive
San Diego, CA 92128
888-635-5840
Quest Diagnostics Incorporated
1777 Montreal Circle
Tucker, GA 30084
800-729-6432
(Formerly: SmithKline Beecham Clinical Laboratories; SmithKline
Bio-Science Laboratories)
Quest Diagnostics Incorporated
400 Egypt Road
Norristown, PA 19403
610-631-4600/877-642-2216
(Formerly: SmithKline Beecham Clinical Laboratories; SmithKline
Bio-Science Laboratories)
Quest Diagnostics Incorporated
8401 Fallbrook Ave.
West Hills, CA 91304
818-737-6370
(Formerly: SmithKline Beecham Clinical Laboratories)
Redwood Toxicology Laboratory
3700650 Westwind Blvd.
Santa Rosa, CA 95403
800-255-2159
Southwest Laboratories
4625 E. Cotton Center Boulevard
Suite 177
Phoenix, AZ 85040
602-438-8507/800-279-0027
STERLING Reference Laboratories
2617 East L Street
Tacoma, Washington 98421
800-442-0438
U.S. Army Forensic Toxicology Drug Testing Laboratory
2490 Wilson St.
Fort George G. Meade, MD 20755-5235
301-677-7085
* The Standards Council of Canada (SCC) voted to end its Laboratory
Accreditation Program for Substance Abuse (LAPSA) effective May 12,
1998. Laboratories certified through that program were accredited to
conduct forensic urine drug testing as required by U.S. Department of
Transportation (DOT) regulations. As of that date, the
[[Page 17444]]
certification of those accredited Canadian laboratories will continue
under DOT authority. The responsibility for conducting quarterly
performance testing plus periodic on-site inspections of those LAPSA-
accredited laboratories was transferred to the U.S. HHS, with the HHS'
NLCP contractor continuing to have an active role in the performance
testing and laboratory inspection processes. Other Canadian
laboratories wishing to be considered for the NLCP may apply directly
to the NLCP contractor just as U.S. laboratories do.
Upon finding a Canadian laboratory to be qualified, HHS will
recommend that DOT certify the laboratory (Federal Register, July 16,
1996) as meeting the minimum standards of the Mandatory Guidelines
published in the Federal Register on April 30, 2010 (75 FR 22809).
After receiving DOT certification, the laboratory will be included in
the monthly list of HHS-certified laboratories and participate in the
NLCP certification maintenance program.
Janine Denis Cook,
Chemist Division of Workplace Programs, Center for Substance Abuse
Prevention, SAMHSA.
[FR Doc. 2015-07423 Filed 3-31-15; 8:45 am]
BILLING CODE 4162-20-P